Vidarabine is neither a potent nor a selective AC5 inhibitor

Biochemical Pharmacology

Volumn 87, Issue 4, 2014, Pages 543-546

  Seifert, Roland ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adenylyl cyclase 5; Cancer; Heart failure; P site inhibitor; Vidarabine

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE 5; ADENYLATE CYCLASE INHIBITOR; CYCLIC AMP; UNCLASSIFIED DRUG; VIDARABINE;

COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG STRUCTURE; FOLLOW UP; HEART FAILURE; HEART MUSCLE FIBER MEMBRANE; HUMAN; NONHUMAN; PARKINSONISM; PHARMACOPHORE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; WILD TYPE;

ADENYLYL CYCLASE 5; CANCER; HEART FAILURE; P-SITE INHIBITOR; VIDARABINE;

ADENYLATE CYCLASE; ANIMALS; ANTIVIRAL AGENTS; HEART FAILURE; HUMANS; ISOENZYMES; NEOPLASMS; VIDARABINE;

EID: 84893737109     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.12.025     Document Type: Note

References (25)

1. F.G. Hayden Antiviral agents (nonretroviral) L.L. Brunton, J.S. Lazo, K.L. Parker, Goodman & Gilman's the pharmacological basis of therapeutics 11th ed. 2006 McGraw-Hill New York, NY 1243 1271 Chapter 49
2. C. Thompson, and R. Whitley Neonatal herpes simplex virus infections: where are we now Advances in Experimental Medicine and Biology 697 2011 221 230
3. J.D. Henderer, and C.J. Rapuno Ocular pharmacology L.L. Brunton, J.S. Lazo, K.L. Parker, Goodman & Gilman's the pharmacological basis of therapeutics 11th ed. 2006 McGraw-Hill New York, NY 1707 1737 Chapter 63
4. S.F. Vatner, M. Park, L. Yan, G.J. Lee, L. Lai, and K. Iwatsubo et al. Adenylyl cyclase type 5 in cardiac disease, metabolism and aging American Journal of Physiology Circulation Physiology 305 2013 H1 H8
5. M.S. De Lorenzo, W. Chen, E. Baljinnyam, M.J. Carlini, K. La Perle, and S.P. Bishop et al. Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase 5 disruption Aging Cell 2013 Doi: 10.111/acel.12152
6. K. Iwatsubo, C. Bravo, M. Uechi, E. Baljinnyam, T. Nakamura, and M. Umemura et al. Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase American Journal of Physiology Circulation Physiology 302 2012 H622 H628
7. T. Iwamoto, S. Okumura, K. Iwatsubo, J.I. Kawabe, K. Ohtsu, and I. Sakai et al. Motor dysfunction in type 5 adenylyl cyclase-null mice Journal of Biological Chemistry 278 2003 16936 16940 (Pubitemid 36799567)
8. R.K. Sunahara, and R. Taussig Isoforms of mammalian adenylyl cyclase: multiplicities of signaling Molecular Interventions 2 2002 168 184
9. R. Sadana, and C.W. Dessauer Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies Neurosignals 17 2009 5 22
10. H. Rehmann, A. Wittinghofer, and J.L. Bos Capturing cyclic nucleotides in action: snapshots from crystallographic studies Nature Reviews in Molecular and Cell Biology 8 2007 63 73 (Pubitemid 46012015)
11. S. Pierre, T. Eschenhagen, G. Geisslinger, and K. Scholich Capturing adenylyl cyclases as potential drug targets Nature Reviews in Drug Discovery 8 2009 321 335
12. R. Seifert, G.H. Lushington, T.C. Mou, A. Gille, and S.R. Sprang Inhibitors of membranous adenylyl cyclases Trends in Pharmacological Sciences 33 2012 64 78
13. M.H. Gao, T. Tang, N.C. Lai, A. Miyanohara, T. Guo, and R. Tang et al. Beneficial effects of adenylyl cyclase 6 (AC6) expression persist using a catalytically inactive AC6 mutant Molecular Pharmacology 79 2011 381 388
14. A. Gille, G.H. Lushington, T.C. Mou, M.B. Doughty, R.A. Johnson, and R. Seifert Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides Journal of Biological Chemistry 279 2004 19955 19969 (Pubitemid 38623438)
15. S.E. Sadler, and J.L. Maller Inhibition of Xenopus oocyte adenylate cyclase by progesterone and 2′,5′-dideoxyadenosone is associated with slowing of guanine nucleotide exchange Journal of Biological Chemistry 258 1983 7935 7941 (Pubitemid 13075263)
16. A. Ibrahimi, N. Abumrad, H. Maghareie, M. Golia, I. Shoshani, and L. Desaubry et al. Adenylyl cyclase P-site ligands accelerate differentiation in Ob1771 preadipocytes American Journal of Physiology 276 1999 C487 C496
17. C.W. Dessauer, J.J. Tesmer, S.R. Sprang, and A.G. Gilman The interactions of adenylate cyclases with P-site inhibitors Trends in Pharmacological Sciences 20 1999 205 210
18. K. Iwatsubo, S. Minamisawa, T. Tsunematsu, M. Nakagome, Y. Toya, and J.E. Tomlinson et al. Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration Journal of Biological Chemistry 279 2004 40938 40945 (Pubitemid 39287693)
19. C.S. Brand, H.J. Hocker, A.A. Gorfe, C.N. Cavasotto, and C.W. Dessauer Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compounds Journal of Pharmacology and Experimental Therapeutics 347 2013 265 275
20. J.H. Bräunig, F. Schweda, P.L. Han, and R. Seifert Similarly potent inhibition of adenylyl cyclase by P-site inhibitors in hearts from wild type and AC5 knockout mice PLoS One 8 2013 e68009
21. J.H. Bräunig, B. Albrecht-Küpper, and R. Seifert Adenylyl cyclase regulation in heart failure due to myocardial infarction in rats Naunyn-Schmiedeberg's Archives of Pharmacology 2014 10.1007/s00210-013-0943-3
22. Y. Bai, T. Tsumamatsu, Q. Jiao, Y. Ohnuki, Y. Mototani, and K. Shiozawa et al. Pharmacological stimulation of type 5 adenylyl cyclase stabilizes heart rate under both microgravity and hypergravity induced by parabolic flight Journal of Pharmacological Sciences 119 2012 381 389
23. N. Musi, T. Hayashi, N. Fuji, M.F. Hirshman, L.A. Witters, and L.J. Goodyear AMP-activated protein kinase activity and glucose uptake in skeletal muscle American Journal of Physiology Endocrinology and Metabolism 280 2001 E677 E684
24. 3 adenosine receptors Naunyn-Schmiedeberg's Archives of Pharmacology 385 2012 519 525
25. E. De Clercq Antivirals for the treatment of herpesvirus infections Journal of Animicrobial Chemotherapy 32 Suppl A 1993 121 132 (Pubitemid 23244716)